Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-27T09:52:12.699Z Has data issue: false hasContentIssue false
  • English
  • Français

The future of radiotherapy and chemotherapy in head and neck cancer

Published online by Cambridge University Press:  08 March 2006

Caroline H. Bridgewater  and
Margaret F. Spittle
Caroline H. Bridgewater
Affiliation:
From The Meyerstein Institute of Oncology, The Middlesex Hospital, Mortimer Street, London, UK.
Margaret F. Spittle
Affiliation:
From The Meyerstein Institute of Oncology, The Middlesex Hospital, Mortimer Street, London, UK.
Get access Rights & Permissions [Opens in a new window]

Abstract

For the 40 per cent of patients with head and neck cancer who present with stage I and II disease either radiotherapy or surgery can be curative. The remaining 60 per cent have advanced loco-regional disease and even when treated with surgery and radiotherapy the five-year survival is less than 30 per cent. Most patients with relapse have loco-regional disease and second primary tumours have an incidence of three per cent a year.1 Current attempts to improve prognosis include the addition of chemotherapy, the use of brachytherapy and accelerated radiotherapy regimes such as continuous hyperfractionated accelerated radiotherapy (CHART).

Keywords

BrachytherapyRadiotherapyRadiosurgeryChemotherapyCisplatinPaclitaxel
Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 114 , Issue 6 , June 2000 , pp. 411 - 413
Copyright
Royal Society of Medicine Press Limited 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)